CVS Health company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
A Yahoo Finance-linked market column says CVS Health is among the stocks getting the most attention from Zacks.com users, prompting renewed focus on what could drive the next phase for the healthcare retailer and pharmacy operator.
THE APEX TIMES
THE APEX TIMES
Truist raised its CVS Health price objective to $108 from $102 while keeping a “Buy” rating, pointing to renewed confidence in the pharmacy and insurance giant’s earnings outlook after a strong first quarter.
THE APEX TIMES
A Yahoo Finance market comparison suggests CVS Health has delivered stronger year-to-date performance than other medical-sector stocks tracked alongside Align Technology.
THE APEX TIMES
A syndicated June 4, 2026 market note pegged CVS Health’s brokerage “average recommendation” at a buy-equivalent level, led by strong-buy ratings from most firms surveyed. The same note cautioned that the metric alone is not a reliable guide to where the stock could go.
THE APEX TIMES
A Zacks Rank upgrade to #2 (Buy) on June 4, 2026 highlighted rising optimism around CVS Health’s earnings trajectory, coming shortly after the company raised its 2026 guidance in its first-quarter results.
THE APEX TIMES
CVS Health said its pharmacy benefit manager will restore coverage of Eli Lilly’s weight-loss injection Zepbound on Oct. 1, and begin covering Lilly’s new oral GLP-1 therapy Foundayo on June 1, reversing a prior coverage restriction.
THE APEX TIMES
The Woonsocket, Rhode Island-based health company marked the groundbreaking of a mixed-use project that preserves a historic church structure while creating housing targeted to families at 30% to 80% of area median income.
THE APEX TIMES
CVS Health’s stock has gained about 8.5% since its last earnings report, after the company posted stronger-than-expected first-quarter results and raised full-year 2026 guidance. The next test is whether improved margins and cost control can hold into the next earnings cycle.
THE APEX TIMES
The rating agency maintained an “A (Excellent)” financial strength rating and an “a (Excellent)” long-term issuer credit rating for Aetna Life Insurance Company and other Aetna Health & Life Group members, citing strong balance-sheet support and stable outlooks, despite pressure on parent leverage from 2024 underwriting results.
